Savara (NASDAQ:SVRA) & Iterum Therapeutics (NASDAQ:ITRM) Financial Survey

Iterum Therapeutics (NASDAQ:ITRM) and Savara (NASDAQ:SVRA) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, institutional ownership, risk, analyst recommendations, profitability, earnings and valuation.

Analyst Ratings

This is a breakdown of current ratings for Iterum Therapeutics and Savara, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Iterum Therapeutics	1	0	1	0	2.00
Savara	1	1	7	1	2.80

Iterum Therapeutics presently has a consensus price target of $9.00, suggesting a potential upside of 2,138.81%. Savara has a consensus price target of $8.29, suggesting a potential upside of 28.86%. Given Iterum Therapeutics’ higher possible upside, equities analysts plainly believe Iterum Therapeutics is more favorable than Savara.

Risk & Volatility

Iterum Therapeutics has a beta of 2.91, meaning that its stock price is 191% more volatile than the S&P 500. Comparatively, Savara has a beta of 0.23, meaning that its stock price is 77% less volatile than the S&P 500.

Profitability

This table compares Iterum Therapeutics and Savara’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Iterum Therapeutics	N/A	N/A	-65.54%
Savara	N/A	-86.60%	-65.44%

Valuation & Earnings

This table compares Iterum Therapeutics and Savara”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Iterum Therapeutics	$390,000.00	54.41	-$24.77 million	($0.75)	-0.54
Savara	N/A	N/A	-$95.88 million	($0.53)	-12.13

Iterum Therapeutics has higher revenue and earnings than Savara. Savara is trading at a lower price-to-earnings ratio than Iterum Therapeutics, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

9.2% of Iterum Therapeutics shares are held by institutional investors. Comparatively, 87.9% of Savara shares are held by institutional investors. 2.4% of Iterum Therapeutics shares are held by insiders. Comparatively, 5.3% of Savara shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Savara beats Iterum Therapeutics on 7 of the 13 factors compared between the two stocks.

About Iterum Therapeutics

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and intravenous formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.

About Savara

Savara Inc., formerly Mast Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients. Molgradex is an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor. It is developing Molgradex for the treatment of autoimmune pulmonary alveolar proteinosis, a rare lung disease. AIR001 is a sodium nitrite solution for inhalation via nebulization. AIR001 is in Phase II clinical development for the treatment of heart failure with preserved ejection fraction, also known as diastolic heart failure or heart failure with preserved systolic function.